Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) has announced plans to report its financial results for the fourth quarter and full year ending December 31, 2021. A corporate update conference call is scheduled for Thursday, March 31, 2022, at 8:00 AM Eastern Time. The company is focused on developing AAV-based gene therapies for treating monogenic diseases in the central nervous system. Taysha combines expertise in drug development with the UT Southwestern Gene Therapy Program to create a robust pipeline aimed at curing these diseases.

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.

Conference Call Details
Thursday, March 31 at 8:00 AM Eastern Time / 7:00 AM Central Time
Toll Free:	877-407-0792
International:	201-689-8263
Conference ID:	13727816
Webcast:	https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005295/en/

Company Contact:

Kimberly Lee, D.O.

Chief Corporate Affairs Officer

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.

FAQ

When will Taysha Gene Therapies report its fourth quarter 2021 financial results?

Taysha Gene Therapies will report its fourth quarter and full year financial results on March 31, 2022.

What time is the Taysha Gene Therapies conference call?

The conference call is scheduled for 8:00 AM Eastern Time on March 31, 2022.

Where can I find the webcast for Taysha's corporate update?

The webcast for Taysha's corporate update can be found at https://ir.tayshagtx.com/news-events/events-presentations.

What is the stock symbol for Taysha Gene Therapies?

The stock symbol for Taysha Gene Therapies is TSHA.